Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 83

Sort by

Sort Order Select

Journal Articles

Comprehensive Analysis of Diagnosis, Treatment and Outcome in a Retrospective Cohort of HES Patients in the South-West of the Netherlands between 2000-2020

Yvonne Veltman, Anton Langerak, Berna Beverloo, Roel Fiets, Henk-Jan Boiten, Pim Mutsaers

Blood (2024) 144 (Supplement 1): 3906.

https://doi.org/10.1182/blood-2024-204613

Published: 2024

Journal Articles

Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL

Roger Mulet-Lazaro, Aniko Sijs-Szabó, Remco Hoogenboezem, Stanley Van Herk, Patricia G. Hoogeveen, Francois Kavelaars, Anita Schelen, Willemijn van den Ancker, Arjan A. van de Loosdrecht, Berna Beverloo, Vincent H.J. Van Der Velden, Jan J. Cornelissen, Peter J. M. Valk, Anita W. Rijneveld, Mathijs Arnoud Sanders

Blood (2024) 144 (Supplement 1): 4300.

https://doi.org/10.1182/blood-2024-209773

Published: 2024

Journal Articles

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. Van Der Velden, H. Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz Seval, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Elena Zamagni, Evangelos Terpos

Blood (2023) 142 (Supplement 1): 1956.

https://doi.org/10.1182/blood-2023-178533

Published: 2023

Journal Articles

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Niek G. Van Der Maas, Dimitri Breems, Clara Klerk, Thomas Pabst, Patrycja Gradowska, Bart J. Biemond, Jurgen Kuball, Janine Van Elssen, Otto Visser, Marie-Christiane Vekemans, Carlos Graux, Johan Maertens, H. Berna Beverloo, Peter J. M. Valk, Gert J. Ossenkoppele, Bob Lowenberg, Geert A. Huls, Jan J. Cornelissen, Jurjen Versluis

Blood (2023) 142 (Supplement 1): 724.

https://doi.org/10.1182/blood-2023-180812

Published: 2023

Journal Articles

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Meral Beksac, Tulin Tuglular, Francesca Gay, Roberto Mina, Eirini Katodritou, Ali Unal, Michele Cavo, Guner Hayri Ozsan, Vincent H.J. van der Velden, Berna Beverloo, Michael Vermeulen, Mark van Duin, Guldane Cengiz, Omur Gokmen Sevindik, Serena Merante, Kyriaki Manousou, Pieter Sonneveld, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 10177–10179.

https://doi.org/10.1182/blood-2022-160004

Published: 2022

Journal Articles

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Blood (2022) 140 (Supplement 1): 1566–1567.

https://doi.org/10.1182/blood-2022-170249

Published: 2022

Journal Articles

Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders

Rob Pieters, Hester A. De Groot-Kruseman, Femke Verwer, Merian van Overveld, Edwin Sonneveld, Marta Fiocco, Vincent H.J. van der Velden, Berna Beverloo, Marc Bierings, Valerie De Haas, Peter M. Hoogerbrugge, Inge M. Van Der Sluis, Wim J.E. Tissing, Margreet Veening, Judith M. Boer, Monique L. den Boer

Blood (2022) 140 (Supplement 1): 519–520.

https://doi.org/10.1182/blood-2022-165931

Published: 2022

Journal Articles

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Blood (2022) 140 (Supplement 1): 8976–8978.

https://doi.org/10.1182/blood-2022-163056

Published: 2022

Journal Articles

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Blood (2022) 139 (15): 2347–2354.

https://doi.org/10.1182/blood.2021014472

Published: 2022

Includes: Supplemental data

Journal Articles

A Phase I/II Study of Bosutinib in Pediatric Patients with Resistant/Intolerant or Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children's Oncology Group Consortium) AAML1921: Results from the Phase I Trial in Resistant/Intolerant Patients

Blood (2021) 138 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2021-145709

Published: 2021

Journal Articles

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Rowan Kuiper, PhD, Mark van Duin, PhD, Martin H Van Vliet, Erik H Van Beers, PhD, Berna Berna Beverloo, PhD, Sonja Zweegman, MD PhD, Tom Cupedo, PhD, Annemiek Broijl, MD PhD, Pieter Sonneveld, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-139987

Published: 2020

Journal Articles

Atypical 3q26/ MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia

Sophie Ottema, Roger Mulet-Lazaro, H. Berna Beverloo, Claudia Erpelinck, Stanley van Herk, Robert van der Helm, Marije Havermans, Tim Grob, Peter J. M. Valk, Eric Bindels, Torsten Haferlach, Claudia Haferlach, Leonie Smeenk, Ruud Delwel

Blood (2020) 136 (2): 224–234.

https://doi.org/10.1182/blood.2019003701

Published: 2020

Includes: Supplemental data

Journal Articles

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Treated with Imids in the HOVON-87/Nmsg-18 Trial Is Associated with Longer PFS and OS

Ruth Wester, M Duin, King Hong Lam, MD PhD, Suzana Couto, Yan Ren, Maria Wang, Bronno Van Der Holt, PhD, Berna Berna Beverloo, PhD, Heleen Visser-Wisselaar, Alex Nigg, Anjan Thakurta, Sonja Zweegman, Annemiek Broyl, MD PhD, Pieter Sonneveld

Blood (2019) 134 (Supplement_1): 3071.

https://doi.org/10.1182/blood-2019-128584

Published: 2019

Journal Articles

Complex 3q26/EVI1 Rearrangements Genocopy Inv(3)/t(3;3) Acute Myeloid Leukemias By Enhancer Hijacking, EVI1 Overexpression, Absent MDS1-EVI1 and Low GATA2 Expression

Sophie Ottema, MSc, Roger Mulet-Lazaro, B.Sc., Berna Beverloo, PhD, Marije Havermans, Ir, Claudia Erpelinck-Verschueren, B.Sc., Tim Grob, MD, Peter Valk, PhD, Eric Bindels, PhD, Torsten Haferlach, MD, Claudia Haferlach, MD, Leonie Smeenk, PhD, Ruud Delwel, PhD

Blood (2018) 132 (Supplement 1): 2766.

https://doi.org/10.1182/blood-2018-99-113339

Published: 2018

Journal Articles

NUTM1 Is a Rare but Recurrent Fusion Gene Partner in B Cell Precursor Acute Lymphoblastic Leukemia Associated with Increased Expression of Genes on Cytoband 10p12.31

Femke M. Hormann, MSc, Alex Q. Hoogkamer, BSc, H. Berna Beverloo, PhD, Aurélie Boeree, BSc, Ronald W. Stam, PhD, Gabriele Escherich, Rob Pieters, MD PhD MSc, Monique L. Den Boer, PhD, Judith M. Boer, PhD

Blood (2018) 132 (Supplement 1): 2823.

https://doi.org/10.1182/blood-2018-99-112480

Published: 2018

Journal Articles

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Davine Hofste Op Bruinink, MD, Vincent van der Velden, PhD, Mark van Duin, PhD, Berna Beverloo, PhD, Jeroen te Marvelde, BSc, Chelsea den Hollander, BSc, Rowan Kuiper, MSc, Michel Delforge, MDPhD, Martin H van Vliet, PhD, Niels WCJ van de Donk, MDPhD, Hervé Avet-Loiseau, MDPhD, Philippe Moreau, MDPhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 4368.

https://doi.org/10.1182/blood.V130.Suppl_1.4368.4368

Published: 2017

Journal Articles

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS

Ruth Wester, King Hong Lam, MD PhD, Mark van Duin, PhD, Suzana Couto, Yan Ren, Maria Wang, PhD, Bronno van der Holt, Berna Beverloo, PhD, Heleen Visser-Wisselaar, Alex Nigg, Max Qian, Anjan Thakurta, PhD, Annemiek Broyl, MD PhD, Sonja Zweegman, MD PhD, Pieter Sonneveld, MDPhD

Blood (2017) 130 (Supplement 1): 3052.

https://doi.org/10.1182/blood.V130.Suppl_1.3052.3052

Published: 2017

Journal Articles

High PDGFRA Expression Does Not Serve As Effective Therapeutic Target in ERG -Deleted B-Cell Precursor Acute Lymphoblastic Leukemia

Isabel S. Jerchel, MSc, Judith M. Boer, PhD, Alex Q. Hoogkamer, BSc, H. Berna Beverloo, PhD, Rob Pieters, MD PhD, Monique L. den Boer, PhD

Blood (2017) 130 (Supplement 1): 1274.

https://doi.org/10.1182/blood.V130.Suppl_1.1274.1274

Published: 2017

Journal Articles

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Blood (2016) 128 (22): 3271.

https://doi.org/10.1182/blood.V128.22.3271.3271

Published: 2016

Journal Articles

Extensive RAG-Mediated Rearrangements and Mutations in BCR-ABL1 and BCR - ABL1 -like Adult Acute Lymphoblastic Leukemia

Mathijs A. Sanders, PhD, Anikó Szabó, MD, Carla Exalto, Remco Hoogenboezem, Annelieke Zeilemaker, Jasper E. Koenders, Peter van Geel, Anita Schelen, H. Berna Beverloo, PhD, Jan J. Cornelissen, MD PhD, Anita W. Rijneveld, MD PhD, Peter J.M. Valk, PhD

Blood (2016) 128 (22): 4067.

https://doi.org/10.1182/blood.V128.22.4067.4067

Published: 2016

NARROW

Comprehensive Analysis of Diagnosis, Treatment and Outcome in a Retrospective Cohort of HES Patients in the South-West of the Netherlands between 2000-2020

Transcriptional Profiling Directs the Classification of Mixed Phenotype Acute Leukemias into AML, B-ALL or T-ALL

Treatment with Daratumumab Plus Bortezomib, Cyclophosphamide, and Dexamethasone May Result in Both Hematologic and Metabolic Complete Response to Achieve Long-Term Progression Free Survival Among Patients Presenting with Extra-Medullary Disease: A European Myeloma Network Study (EMN19)

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Efficacy of Daratumumab Combined with Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting with Extramedullary Disease: A European Myeloma Network Study (EMN19)

Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification

Dutch ALL11 Study: Improved Outcome for Acute Lymphoblastic Leukemia By Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for ETV6::RUNX1, Down Syndrome and Prednisone Poor Responders

Inotuzumab Ozogamicin (InO) Combined with UKALL-R3 Modified Chemotherapy in Pediatric Patients with B-Cell Precursor CD22+ Acute Lymphoblastic Leukemia (BCP-ALL) - Results from the ITCC-059 Phase 1B Trial

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

The Prognostic Power of Gene Expression Profiling with Cytogentics and Routinely Acquired Serum Markers: SKY92 Combined with Revised ISS

Atypical 3q26/ MECOM rearrangements genocopy inv(3)/t(3;3) in acute myeloid leukemia

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Treated with Imids in the HOVON-87/Nmsg-18 Trial Is Associated with Longer PFS and OS

Complex 3q26/EVI1 Rearrangements Genocopy Inv(3)/t(3;3) Acute Myeloid Leukemias By Enhancer Hijacking, EVI1 Overexpression, Absent MDS1-EVI1 and Low GATA2 Expression

NUTM1 Is a Rare but Recurrent Fusion Gene Partner in B Cell Precursor Acute Lymphoblastic Leukemia Associated with Increased Expression of Genes on Cytoband 10p12.31

The Level of Circulating Myeloma Cells at Diagnosis Correlates with a Plasma Cell Leukemia-like Phenotype of the Corresponding Myeloma Cells in Bone Marrow

Higher Expression of Nuclear Cereblon in Bone Marrow Biopsies of Patients with Multiple Myeloma Included in the HOVON-87/Nmsg-18 Trial May be Associated with Longer PFS and OS

High PDGFRA Expression Does Not Serve As Effective Therapeutic Target in ERG -Deleted B-Cell Precursor Acute Lymphoblastic Leukemia

Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis

Extensive RAG-Mediated Rearrangements and Mutations in BCR-ABL1 and BCR - ABL1 -like Adult Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only